Association Of Lifestyle Modification and Pharmacological Therapy with Clinical Outcomes and Medication Adherence Among Patients with Coronary Artery Disease: A Prospective Observational Study

Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide and remains a major public health challenge despite advances in diagnosis and treatment [1]. It is characterized by progressive atherosclerotic narrowing of the coronary arteries, leading to myocardial ischemia, acute coronary syndromes, heart failure, and sudden cardiac death[2]. The growing prevalence of hypertension, diabetes mellitus, dyslipidaemia, smoking, obesity, and sedentary lifestyles has contributed substantially to the increasing burden of CAD, particularly in developing countries such as India [1,2].

Evidence-based pharmacological therapy is the cornerstone of CAD management and secondary prevention. Antiplatelet agents, statins, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and anti-anginal medications have consistently been shown to reduce recurrent cardiovascular events and improve long-term prognosis[6]. Pharmacological therapy primarily targets thrombosis, dyslipidaemia, hypertension, and myocardial oxygen demand, whereas lifestyle modification addresses modifiable cardiovascular risk factors such as smoking, physical inactivity, obesity, unhealthy dietary habits, and poor dietary practices. Together, these complementary strategies form the foundation of comprehensive secondary prevention in patients with coronary artery disease [6].

Despite the availability of effective therapies, poor adherence to pharmacological treatment and inadequate implementation of lifestyle recommendations remains major barriers to successful secondary prevention. These challenges are associated with recurrent cardiovascular events, increased hospitalizations, higher healthcare costs, and reduced quality of life. Recent original studies have demonstrated that patient education, pharmacist-led interventions, and digital health programmes significantly improve medication adherence and support long-term disease management in patients with coronary artery disease[8].

Considering these challenges, the present prospective observational study was undertaken to evaluate the impact of combined lifestyle modification and pharmacological therapy on medication adherence among patients with coronary artery disease. The study further assessed demographic characteristics, disease profile, comorbidity profile, drug utilization patterns, surgical management, and adherence to recommended lifestyle modifications to generate real-world evidence supporting comprehensive secondary prevention strategies.

PATHOPHYSIOLOGY OF CAD:

Coronary artery disease (CAD) is a chronic inflammatory disorder characterized by the progressive development of atherosclerotic plaques within the coronary arteries[3,4], leading to impaired myocardial perfusion. The disease process begins with endothelial dysfunction caused by cardiovascular risk factors such as hypertension, diabetes mellitus, dyslipidemia, smoking, obesity, and sedentary lifestyle. Endothelial injury promotes the infiltration of low-density lipoprotein (LDL) cholesterol into the arterial wall, where it undergoes oxidation and triggers an inflammatory response. Activated macrophages engulf oxidized LDL particles to form foam cells, resulting in fatty streaks that gradually progress to fibrous atherosclerotic plaques [3]. As plaque burden increases, coronary blood flow becomes restricted, producing myocardial ischemia and clinical manifestations such as stable angina. Plaque rupture or erosion may precipitate platelet activation and thrombus formation, leading to acute coronary syndromes, including unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) [4]. Major modifiable risk factors, including hypertension, diabetes mellitus, dyslipidaemia, smoking, obesity, physical inactivity, and unhealthy dietary habits, accelerate the progression of atherosclerosis and increase the risk of adverse cardiovascular events [5].The progression of coronary artery disease is strongly influenced by modifiable cardiovascular risk factors. Effective control of hypertension, diabetes mellitus, dyslipidemia, smoking, obesity, and sedentary behavior, together with adherence to guideline-directed pharmacological therapy, plays a critical role in slowing disease progression and reducing recurrent cardiovascular events. Consequently, comprehensive management strategies that integrate pharmacological treatment with sustained lifestyle modification constitute the foundation of contemporary secondary prevention for patients with coronary artery disease [5].

LIFE STYLE MODIFICATION:

Lifestyle modification is a fundamental component of both primary and secondary prevention of coronary artery disease and complements evidence-based pharmacological therapy [11]. International cardiovascular guidelines recommend smoking cessation, regular physical activity, adherence to a heart-healthy diet, weight management, stress reduction, moderation of alcohol intake, and participation in structured cardiac rehabilitation programmes [11]. These interventions improve endothelial function, reduce systemic inflammation, enhance metabolic control, and contribute to long-term cardiovascular risk reduction [5,11]. However, adherence to lifestyle recommendations remains suboptimal in routine clinical practice because of inadequate patient awareness, poor motivation, limited follow-up, and socioeconomic barriers [2].  Recent original clinical studies have demonstrated that structured health education, pharmacist-led counselling, and digital health interventions significantly improve medication adherence, lifestyle compliance, and overall disease management among patients with coronary artery disease[12].

PHARMACOLOGY TREATMENT:

Evidence-based pharmacological therapy forms the cornerstone of CAD management and secondary prevention [6,7]. Current international guidelines recommend antiplatelet agents, statins, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), nitrates, and other adjunctive therapies based on the patient's clinical presentation and associated comorbidities[6,7]. Antiplatelet agents reduce thrombotic complications by inhibiting platelet aggregation, while statins lower LDL cholesterol levels, stabilize atherosclerotic plaques, and slow disease progression [8].  Beta-blockers decrease myocardial oxygen demand by reducing heart rate and blood pressure, whereas ACE inhibitors and ARBs improve vascular function and reduce cardiovascular events, particularly in patients with hypertension, diabetes mellitus, left ventricular dysfunction, or heart failure [8,9]. Large randomized clinical trials, including the COURAGE and ISCHEMIA trials, have demonstrated that optimal medical therapy remains the foundation of CAD management regardless of whether invasive coronary revascularization is performed [6,7]. Furthermore, adherence to evidence-based pharmacotherapy has been consistently associated with improved long-term cardiovascular outcomes, emphasizing the importance of sustained medication adherence in secondary prevention [8,10].

Overview of Guideline-Directed Pharmacological Therapy for Coronary Artery Disease

Table 2. Overview of guideline-directed pharmacological therapy recommended for the management of coronary artery disease and acute coronary syndrome.

AIM OF THE STUDY

The present prospective observational study was conducted to evaluate the association of combined lifestyle modification and pharmacological therapy with clinical outcomes and medication adherence among patients with coronary artery disease admitted to a tertiary care hospital. The study also aimed to describe patient demographics, disease characteristics, comorbidity profile, drug utilization patterns, surgical management, and adherence to recommended lifestyle modifications, thereby providing real-world evidence to support comprehensive secondary prevention strategies in CAD.

MATERIALS AND METHODS

Study Design

A prospective observational study was conducted to evaluate the association of combined lifestyle modification and pharmacological therapy with clinical outcomes and medication adherence among patients diagnosed with coronary artery disease (CAD). The study was designed to observe real-world treatment practices, assess adherence to prescribed medications and recommended lifestyle interventions, and evaluate their association with clinical outcomes without influencing the therapeutic decisions made by treating physicians. The observational design enabled the assessment of routine clinical management under standard hospital practice while minimizing intervention-related bias.

Study Setting

The study was carried out in the Department of Cardiology of a tertiary care teaching hospital in Hyderabad, Telangana, India. The hospital serves a large and diverse patient population from both urban and rural regions, providing comprehensive cardiovascular care including emergency management, inpatient services, diagnostic investigations, and long-term follow-up of patients with coronary artery disease.

Study Duration

The study was conducted over a period of six months, during which eligible patients were consecutively enrolled, monitored, and evaluated according to the predefined study objectives. Data collection was performed prospectively throughout the study period.

Study Population

The study population consisted of adult patients diagnosed with coronary artery disease who were admitted to or attended the Department of Cardiology during the study period. Eligible patients were recruited consecutively after confirmation of diagnosis by the treating cardiologist based on clinical evaluation and relevant diagnostic investigations.

Sample Size

A total of 100 patients meeting the eligibility criteria were included in the study. The sample size was determined based on the availability of eligible patients during the study period and was considered adequate for evaluating treatment patterns, medication adherence, lifestyle modification practices, and associated clinical outcomes in this prospective observational study.

Eligibility Criteria

Inclusion Criteria

Patients were considered eligible if they fulfilled all of the following criteria:

• Adult patients aged 20–80 years.
• Diagnosed with coronary artery disease with clinical features of angina.
• Receiving pharmacological treatment for CAD.
• Patients with associated comorbidities such as hypertension, diabetes mellitus, or dyslipidaemia.
• Patients with or without a history of smoking or alcohol consumption.
• Patients willing to provide written informed consent and participate in the study.

Exclusion Criteria

Patients were excluded if they met any of the following conditions:

• Age below 20 years or above 80 years.
• Pregnant or lactating women.
• Patients with severe hepatic or renal dysfunction.
• Pediatric patients.
• Patients unwilling to participate in the study or unable to provide informed consent.

Data Collection

Patient data were collected prospectively using a standardized and revalidated data collection form specifically designed for the study. Information was obtained from patients' medical records, laboratory reports, physician notes, medication charts, and direct patient interviews.

The following variables were recorded:

Demographic Characteristics

• Age
• Gender
• Body weight
• Social history

Clinical Characteristics

• Primary diagnosis
• Duration of coronary artery disease
• Presenting symptoms
• Comorbidities
• Previous cardiovascular history

Laboratory Parameters

Available laboratory investigations included:

• Cardiac biomarkers

• Lipid profile
• Blood glucose levels
• Renal function tests
• Other relevant biochemical investigations performed during routine clinical care

Diagnostic Investigations

Clinical diagnosis was confirmed using one or more of the following investigations:

• Electrocardiography (ECG)
• Echocardiography
• Coronary angiography
• Cardiac biomarkers
• Additional investigations as indicated by the treating cardiologist

Pharmacological Therapy

Details regarding prescribed medications were documented, including:

• Antiplatelet agents
• Anticoagulants
• Statins
• Beta-blockers
• ACE inhibitors/ARBs
• Calcium channel blockers
• Nitrates
• Diuretics
• Other cardiovascular medications

LIFESTYLE MODIFICATION:

Information regarding adherence to recommended lifestyle interventions was collected, including:

• Smoking cessation
• Dietary modification
• Physical activity
• Weight management
• Alcohol restriction
• Stress management

MEDICATION ADHERENCE:

Medication adherence was assessed during follow-up by reviewing patient compliance with prescribed pharmacological therapy according to physician recommendations. The specific adherence assessment method, criteria, and threshold used to classify a participant as adherent should be stated explicitly before submission.

OUTCOME MEASURES:

Primary Outcome

The primary outcome was the clinical outcome measure used to compare patients adhering to both pharmacological therapy and recommended lifestyle modification with those receiving pharmacological therapy alone.

Secondary Outcomes

Secondary outcomes included:

• Assessment of medication adherence.
• Evaluation of lifestyle modification adherence.
• Identification of common pharmacological treatment patterns.
• Assessment of the prevalence of cardiovascular risk factors and comorbidities.

STATISTICAL ANALYSIS:

All collected data were entered into Microsoft Excel and analyzed using IBM SPSS Statistics (IBM Corp., Armonk, NY, USA). The exact software version should be added before submission. Continuous variables were summarized as mean ± standard deviation (SD) or median with interquartile range (IQR), depending on data distribution, while categorical variables were expressed as frequencies and percentages.

The normality of continuous variables was assessed before inferential analysis. As the outcome data did not satisfy the assumptions of normality, non-parametric statistical methods were applied. The Mann–Whitney U test was used to compare the predefined clinical outcome measure between patients who adhered to both guideline-directed pharmacological therapy and recommended lifestyle modification and those who adhered to pharmacological therapy without documented lifestyle modification adherence. A two-tailed p-value of <0.05 was considered statistically significant.

Descriptive statistics were used to summarize demographic characteristics, comorbidity profiles, drug utilization patterns, medication adherence, lifestyle modification practices, and clinical outcomes.

LIMITATIONS OF THE STUDY

The present study has several limitations that should be considered while interpreting the findings. First, the study was conducted at a single tertiary care teaching hospital with a relatively small sample size, which may limit the generalizability of the results to other healthcare settings and populations. Second, the observational study design precludes establishing a causal relationship between combined lifestyle modification, pharmacological therapy, and improved clinical outcomes. Third, the follow-up period of six months may not adequately capture long-term medication adherence, sustained lifestyle modifications, or recurrent cardiovascular events. Furthermore, lifestyle adherence was primarily assessed through patient-reported information, making the findings susceptible to recall and reporting bias. Despite these limitations, the study provides valuable real-world evidence regarding the beneficial role of integrating lifestyle modification with guideline-directed pharmacological therapy in improving clinical outcomes among patients with coronary artery disease. Future multicenter studies involving larger sample sizes, longer follow-up durations, and more comprehensive statistical analyses are warranted to validate these findings and strengthen the evidence for integrated secondary prevention strategies [2,5,6,11,12,13].

CLINICAL IMPLICATIONS

The findings of the present study have important implications for routine clinical practice. While pharmacological therapy remains the cornerstone of coronary artery disease management, the results indicate that optimal patient outcomes are more likely to be achieved when evidence-based medication is complemented by sustained lifestyle modification.

Healthcare professionals should prioritize comprehensive patient education regarding medication adherence, smoking cessation, dietary modification, regular physical activity, weight management, and control of cardiovascular risk factors. Establishing multidisciplinary care models involving cardiologists, clinical pharmacists, nurses, dietitians, and rehabilitation specialists may improve adherence to therapeutic recommendations and facilitate long-term secondary prevention.

The study also emphasizes the need for structured follow-up programs that monitor medication adherence and reinforce lifestyle counselling after hospital discharge. Such interventions may reduce recurrent cardiovascular events, improve quality of life, decrease healthcare utilization, and contribute to more cost-effective management of coronary artery disease.

From a public health perspective, the findings support the development of hospital-based and community-based cardiovascular prevention programs that integrate pharmacological treatment with behavioural and lifestyle interventions. Strengthening these preventive strategies may help reduce the growing burden of coronary artery disease, particularly in low- and middle-income countries where cardiovascular risk factors continue to increase.

RESULTS

3.1 Baseline Demographic Characteristics

A total of 100 consecutive patients diagnosed with coronary artery disease (CAD) were enrolled during the six-month study period. Among them, 64 (64%) were male and 36 (36%) were female, demonstrating a clear male predominance in the study population (Table 1).

Table 1. Baseline Demographic Characteristics of the Study Population (n = 100)

3.2 Distribution of Social Habits

Table 2. Distribution of Social Habits Among Study Participants

Most participants (61%) reported no history of smoking, alcohol consumption, or tobacco use. Alcohol consumption was the most common social habit (28%), whereas smoking alone (4%) and combined smoking with alcohol consumption (4%) were relatively uncommon. Tobacco chewing was observed in only 1% of patients, while 2% reported both smoking and tobacco chewing (Table 2).

3.3 Clinical Diagnosis Profile

Acute coronary syndrome with unstable angina was the most frequent diagnosis (52%), followed by acute anterior wall myocardial infarction (16%). Non-ST-elevation myocardial infarction and acute coronary syndrome without specified infarction each accounted for 11% of cases. Other clinical diagnoses, including inferior wall myocardial infarction, isolated coronary artery disease, dilated cardiomyopathy, and regional wall motion abnormalities, were less frequently encountered (Table 3).

Table 3. Clinical Diagnosis of Study Participants

3.4 Distribution of Comorbidities

Hypertension and type 2 diabetes mellitus were the most prevalent comorbid conditions observed among the study participants. Combined hypertension and diabetes mellitus represented the largest comorbidity group in both males (21 cases) and females (18 cases). Hypertension alone was more frequently observed among male patients (22 cases) than females (2 cases). Fifteen patients had no documented comorbidities, while hypothyroidism and other medical conditions were reported in a small proportion of participants (Table 4).

Table 4. Distribution of Comorbidities According to Gender

3.5 Surgical Management

Most patients (89%) underwent coronary revascularization procedures, including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG). Eleven patients (11%) did not undergo the planned intervention (Table 5).

Table 5. Surgical Management

3.6 Drug Utilization Pattern

Antiplatelet agents represented the largest proportion of prescribed medications (14.15%), followed by anticoagulants (13.21%), statins (12.26%), proton pump inhibitors (11.59%), and antihypertensive agents (8.49%). Supportive medications collectively accounted for 21.09% of all prescriptions (Table 6).

Table 6. Drug Utilization Pattern

3.7 Medication Adherence and Lifestyle Modification

Medication adherence was reported in all enrolled patients (100%). However, adherence to recommended lifestyle modification was substantially lower. Forty-seven patients (47%) successfully adopted the advised lifestyle changes, whereas 37% did not follow the recommendations and 16% were lost to follow-up before completion of the study (Table 7).

Table 7. Medication Adherence and Lifestyle Modification

Statistical Analysis

To evaluate the effectiveness of combined lifestyle modification and pharmacological therapy on clinical outcomes, a Mann–Whitney U test (Rank Sum Test) was performed to compare two independent groups: patients who adhered to both medication and recommended lifestyle modification (Group 1; n = 37) and patients who adhered to medication alone without lifestyle modification (Group 2; n = 44). The Mann–Whitney U test was selected because the outcome data were not normally distributed and did not satisfy the assumptions required for parametric testing.

Table 8. Mann–Whitney U Test Comparing Clinical Outcomes Between Study Groups